Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9872841 | 1.00 | LMNA (0.45) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL9872454 | 1.00 | LMNA (0.45) | LMNAPOLBRAB9AMEN1NPC1 | |
| SCHEMBL9114789 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9873057 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9873178 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9873430 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9113426 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9873666 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9872933 | 0.91 | LMNA (0.52) | LMNAPOLB | |
| SCHEMBL9873092 | 0.89 | LMNA (0.56) | LMNAPOLBRAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991017150-A1 | TETRAZOLE UREA AND THIOUREA ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1991-11-14 | — | — | WO | claimed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-5073565-A | Atherosclerosis, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1991-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | LMNA 4702/4885POLB 2694/4885RAB9A 4184/4885 |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | LMNA 4702/4885POLB 2694/4885RAB9A 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.